| HOME >> BIOLOGY >> TECHNOLOGY |
Collaboration Highlights Education and Finger Health in Diabetes Management
PALO ALTO, Calif., and INDIANAPOLIS, April 16 /PRNewswire/ -- Pelikan Technologies Inc., a leading developer of innovative hand-held diagnostic and monitoring devices, and Eli Lilly and Company today announced the signing of a three-year co-promotion agreement. Under the terms of the co-promotion agreement, the companies will promote awareness and education in the management and treatment of diabetes, including insulin therapy, insulin delivery devices and technological advancements in lancing designed to optimize Finger Health and Glucose Monitoring.
Self-monitoring of blood glucose is a key component of effective diabetes management. People with diabetes must regularly monitor their blood glucose levels, which requires drawing of a drop of blood, ideally from the tips of their fingers, multiple times each day with a lancing device. According to the American Diabetes Association's position statement "Standards of Medical Care in Diabetes - 2007," most people with type 1 diabetes, as well as people with diabetes who use multiple insulin injections, should test their blood glucose three or more times per day.
Pelikan Technologies Inc.'s Pelikan Sun(TM) electronic lancing device is the world's first and only electronic lancing system, which can offer unprecedented comfort while allowing existing finger damage to heal. Such advances are particularly important for children, people newly-diagnosed with diabetes and people who test their blood glucose frequently. The Pelikan Sun device also offers a key advantage in the area of convenience: its lancets are safely housed in a 50-lancet disk, meaning users never have to see or touch the lancets. The disk is easily removed from the device and replaced as needed.
Through their alliance, Pelikan and Lilly seek to advance diabetes care
education by raising awareness of lifestyle management, diabetes therapies,
and new lanc
'/>"/>
| SOURCE Pelikan Technologies Inc. Copyright©2008 PR Newswire. All rights reserved |